Organovo (NASDAQ:ONVO – Get Rating) and Exscientia (NASDAQ:EXAI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Valuation & Earnings
This table compares Organovo and Exscientia’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Organovo||$1.50 million||9.00||-$11.45 million||($1.37)||-1.13|
|Exscientia||$37.00 million||21.08||-$67.70 million||($1.99)||-3.20|
Organovo has higher earnings, but lower revenue than Exscientia. Exscientia is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Exscientia has a consensus price target of $15.67, suggesting a potential upside of 145.94%. Given Exscientia’s higher possible upside, analysts plainly believe Exscientia is more favorable than Organovo.
This table compares Organovo and Exscientia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
23.0% of Organovo shares are owned by institutional investors. Comparatively, 27.8% of Exscientia shares are owned by institutional investors. 4.0% of Organovo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Exscientia beats Organovo on 7 of the 12 factors compared between the two stocks.
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.